Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
The launch comes against the backdrop of a significant public health burden
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
We are building the bridge between complex molecular data and everyday clinical decisions
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Subscribe To Our Newsletter & Stay Updated
